Jason Luke, MD

Jason Luke, MD, associate director for clinical research and director of the Immunotherapy and Drug Development Center at Hillman Cancer Center, University of Pittsburgh.

Articles

Dr Luke on the Role of IMA203 in Previously Treated Advanced Cutaneous Melanoma

June 6th 2025

Jason Luke, MD, discusses IMA203 vs investigator’s choice of standard therapy in patients with previously treated advanced cutaneous melanoma.

Breaking Down the Data in Genitourinary, Gastrointestinal, and Breast Cancers, Plus Sarcoma and Melanoma at ASCO 2023: Drs Rini, Lewis, Trent, Luke, Kunz, and Lustberg

June 6th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

Dr Luke on Initial Data From the GLIMMER-01 Trial of E-602 in Advanced Solid Tumors

April 20th 2023

Jason J. Luke, MD, FACP, discusses initial results from the phase 1 GLIMMER-01 trial of E-602 in advanced solid tumors.

Dr. Luke on the Importance of a Multidisciplinary Approach in Basal Cell Carcinoma

June 30th 2022

Jason Luke, MD, FACP, discusses the importance of a multidisciplinary approach in basal cell carcinoma.

Dr. Luke on Toxicities With Targeted Therapy Vs Immunotherapy in Melanoma

December 1st 2021

Jason J. Luke, MD, FACP, discusses the toxicities with targeted therapy vs immunotherapy and management strategies for patients with melanoma. 

Dr. Luke on the Results of the Phase 3 KEYNOTE-716 Trial in Melanoma

September 19th 2021

Jason J. Luke, MD, FACP, discusses the results of the phase 3 KEYNOTE-716 trial in high-risk stage II melanoma.

Dr. Luke on Predictive Versus Prognostic Biomarkers in Melanoma

January 6th 2021

Jason J. Luke, MD, FACP, compares predictive and prognostic biomarkers in melanoma.

Dr. Luke the Role of Molecular Testing in Melanoma

November 24th 2020

Jason J. Luke, MD, FACP, discusses the role of molecular testing in melanoma.

Dr. Luke on the Role of Targeted Therapy in Melanoma

November 4th 2020

Jason J. Luke, MD, FACP, discusses the role of targeted therapy in melanoma.

Dr. Luke on the Importance of BRAF in Melanoma

October 28th 2020

Jason J. Luke, MD, FACP, discusses the importance of BRAF in melanoma.

Dr. Luke on the Clinical Trial Landscape for Melanoma

November 29th 2017

Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the clinical trial landscape for melanoma

Dr. Luke on the Future Role of Immunotherapy Combinations in Melanoma

November 10th 2017

Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the future of immunotherapy combinations for patients with melanoma.

Dr. Luke on the Combination of Pembrolizumab and T-VEC for Melanoma

October 28th 2017

Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the combination of pembrolizumab (Keytruda) and talimogene laherparepvec (T-VEC; Imlygic) for the treatment of patients with melanoma.

Dr. Luke Discusses PD-1 Plus IDO Inhibitors in Melanoma

October 19th 2017

Jason Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the combination approach of a PD-1 antibody plus an IDO inhibitor for patients with melanoma.

Dr. Luke on Impactful Data in the Field of Melanoma

October 10th 2017

Jason Luke, MD, an assistant professor of medicine at the University of Chicago Medicine, discusses impactful data in the field of melanoma.

Dr. Luke on Challenges With Immunotherapy in Melanoma

December 20th 2016

Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses some of the challenges that oncologists may face when administering immunotherapy agents to patients with melanoma.

Dr. Jason Luke on Sequencing Targeted and Immunotherapy Agents in BRAF+ Melanoma

November 4th 2016

Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses the role for immunotherapy and targeted agents in patients with BRAF-positive melanoma.

Dr. Luke on Immunotherapy Diagnostics in Melanoma

October 20th 2016

Jason Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses the various methods involved in immunotherapy diagnostics in the treatment landscape of melanoma.

Dr. Jason Luke on Potential for IDO Inhibitors in Melanoma

October 13th 2016

Jason Luke, MD, Assistant Professor of Medicine, The University of Chicago Medicine, discusses IDO inhibitors in melanoma.

Dr. Jason Luke on Utilizing the Tumor Microenvironment as a Biomarker for Immunotherapy Response

November 20th 2015

Jason Luke, MD, Assistant Professor of Medicine, the University of Chicago Medicine Comprehensive Cancer Center, discusses how inflammation in the tumor microenvironment can serve as a biomarker in melanoma.

x